GT200900019AA - Peptidomimeticos de smac utiles como inhibidores de proteinas de apoptosis (aip) - Google Patents
Peptidomimeticos de smac utiles como inhibidores de proteinas de apoptosis (aip)Info
- Publication number
- GT200900019AA GT200900019AA GT200900019AK GT200900019K GT200900019AA GT 200900019A A GT200900019A A GT 200900019AA GT 200900019A K GT200900019A K GT 200900019AK GT 200900019 K GT200900019 K GT 200900019K GT 200900019A A GT200900019A A GT 200900019AA
- Authority
- GT
- Guatemala
- Prior art keywords
- smac
- aip
- peptidomimetics
- inhibitors
- useful
- Prior art date
Links
- 101150082208 DIABLO gene Proteins 0.000 title 1
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 title 1
- 230000006907 apoptotic process Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000816 peptidomimetic Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
LA PRESENTE INVENCIÓN ESTÁ DIRIGIDA A UN COMPUESTO DE LA FÓRMULA (I)O SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS Y EL USO DE TALES COMPUESTOS PARA EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS TALES COMO CÁNCER, EN MAMÍFEROS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83500006P | 2006-08-02 | 2006-08-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT200900019AA true GT200900019AA (es) | 2015-11-24 |
Family
ID=38686647
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT200900019A GT200900019A (es) | 2006-08-02 | 2009-01-30 | Compuestos organicos |
| GT200900019AK GT200900019AA (es) | 2006-08-02 | 2013-10-23 | Peptidomimeticos de smac utiles como inhibidores de proteinas de apoptosis (aip) |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT200900019A GT200900019A (es) | 2006-08-02 | 2009-01-30 | Compuestos organicos |
Country Status (41)
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2253614T3 (pl) | 2004-04-07 | 2013-03-29 | Novartis Ag | Inhibitory IAP |
| ES2475207T3 (es) | 2004-07-15 | 2014-07-10 | Tetralogic Pharmaceuticals Corporation | Compuestos de unión a IAP |
| KR20120127754A (ko) | 2004-12-20 | 2012-11-23 | 제넨테크, 인크. | Ｉａｐ의 피롤리딘 억제제 |
| DK1851200T3 (da) | 2005-02-25 | 2014-04-14 | Tetralogic Pharm Corp | Dimere iap-inhibitorer |
| CA2607940C (en) | 2005-05-18 | 2009-12-15 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| CA2564872C (en) | 2005-10-25 | 2010-12-21 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
| TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| SG10201407457UA (en) | 2006-05-16 | 2014-12-30 | Pharmascience Inc | Iap bir domain binding compounds |
| AR064235A1 (es) | 2006-07-24 | 2009-03-25 | Tetralogic Pharmaceuticals Cor | Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer |
| US20100056495A1 (en) * | 2006-07-24 | 2010-03-04 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| JP5228202B2 (ja) | 2006-07-24 | 2013-07-03 | テトラロジック ファーマシューティカルズ コーポレーション | 二量体ｉａｐアンタゴニスト |
| WO2008057172A2 (en) * | 2006-10-19 | 2008-05-15 | Novartis Ag | Organic compounds |
| BRPI0719559A2 (pt) * | 2006-11-28 | 2014-01-21 | Novartis Ag | Uso de inibidores de iap para o tratamento de leucemia mieloide aguda |
| JP5394249B2 (ja) * | 2006-11-28 | 2014-01-22 | ノバルティス アーゲー | Ｉａｐ阻害剤とｆｌｔ３阻害剤の組合せ剤 |
| WO2008079735A1 (en) * | 2006-12-19 | 2008-07-03 | Genentech, Inc. | Imidazopyridine inhibitors of iap |
| CA2683392A1 (en) | 2007-04-30 | 2008-11-06 | Genentech, Inc. | Inhibitors of iap |
| CA2724720A1 (en) * | 2008-05-16 | 2009-11-19 | Novartis Ag | Immunomodulation by iap inhibitors |
| JP2011529962A (ja) | 2008-08-02 | 2011-12-15 | ジェネンテック， インコーポレイテッド | Ｉａｐのインヒビター |
| US8841067B2 (en) | 2009-01-09 | 2014-09-23 | Dana-Farber Cancer Institute, Inc. | NOL3 is a predictor of patient outcome |
| US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
| US20110034469A1 (en) | 2009-08-04 | 2011-02-10 | Takeda Pharmaceutical Company Limited | Heterocyclic Compound |
| WO2011019782A1 (en) * | 2009-08-11 | 2011-02-17 | Novartis Ag | Combinations of vascular disrupting agents with inhibitor of apoptosis proteins antagonists |
| KR20120048008A (ko) | 2009-08-12 | 2012-05-14 | 노파르티스 아게 | 아폽토시스 단백질의 억제제의 고체 경구 제제 및 결정질 형태 |
| KR20120140658A (ko) | 2010-02-12 | 2012-12-31 | 파마사이언스 인크. | Ｉａｐ ｂｉｒ 도메인 결합 화합물 |
| UY33236A (es) * | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
| DK2611797T3 (en) * | 2010-08-31 | 2017-02-13 | Hanmi Science Co Ltd | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSE-INducing ACTIVITY ON CELLS |
| WO2012052758A1 (en) | 2010-10-22 | 2012-04-26 | Astrazeneca Ab | Response biomarkers for iap antagonists in human cancers |
| UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
| US9227982B2 (en) | 2011-07-13 | 2016-01-05 | Novartis Ag | 4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrminidinyl compounds for use as tankyrase inhibitors |
| WO2013012723A1 (en) | 2011-07-13 | 2013-01-24 | Novartis Ag | Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
| WO2013049350A1 (en) | 2011-09-30 | 2013-04-04 | Tetralogic Pharmaceuticals Corporation | Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer) |
| US8859541B2 (en) * | 2012-02-27 | 2014-10-14 | Boehringer Ingelheim International Gmbh | 6-alkynylpyridines |
| JP6267193B2 (ja) * | 2012-05-22 | 2018-01-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 置換ジピリジルアミン類及びそれらの使用 |
| KR20140011773A (ko) * | 2012-07-19 | 2014-01-29 | 한미약품 주식회사 | 이중 저해 활성을 갖는 헤테로고리 유도체 |
| MX2015014861A (es) | 2013-05-01 | 2016-03-09 | Hoffmann La Roche | Pirimidinas sustituidas con heterocicloalquilo c-enlazado y sus usos. |
| CN105451726B (zh) | 2013-06-25 | 2021-03-16 | 沃尔特和伊利莎豪医学研究所 | 治疗细胞内感染的方法 |
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| LT3116909T (lt) | 2014-03-14 | 2020-02-10 | Novartis Ag | Antikūno molekulės prieš lag-3 ir jų panaudojimas |
| CA2960824A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of alk inhibitors |
| ES2774448T3 (es) | 2014-10-03 | 2020-07-21 | Novartis Ag | Terapias de combinación |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| JP6877339B2 (ja) | 2014-10-14 | 2021-05-26 | ノバルティス アーゲー | Ｐｄ−ｌ１に対する抗体分子およびその使用 |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| JP6692826B2 (ja) | 2015-03-10 | 2020-05-13 | アドゥロ バイオテック，インク． | 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法 |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| EP3964528A1 (en) | 2015-07-29 | 2022-03-09 | Novartis AG | Combination therapies comprising antibody molecules to lag-3 |
| WO2017019896A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| LT3370768T (lt) | 2015-11-03 | 2022-05-25 | Janssen Biotech, Inc. | Antikūnai, specifiškai surišantys pd-1, ir jų panaudojimas |
| EP4424322A3 (en) | 2015-12-17 | 2025-04-16 | Novartis AG | Antibody molecules to pd-1 and uses thereof |
| EP3445759A1 (en) | 2016-04-20 | 2019-02-27 | GlaxoSmithKline Intellectual Property Development Ltd | Conjugates comprising ripk2 inhibitors |
| GB201610147D0 (en) | 2016-06-10 | 2016-07-27 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| CN106496213B (zh) * | 2016-09-30 | 2019-08-20 | 东南大学 | Lcl161前药及其制备方法和应用 |
| JP6899993B2 (ja) * | 2016-10-04 | 2021-07-07 | 国立医薬品食品衛生研究所長 | 複素環化合物 |
| KR20190130644A (ko) | 2017-03-31 | 2019-11-22 | 베링거 인겔하임 인터내셔날 게엠베하 | 항암 조합 요법 |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| US11312783B2 (en) | 2017-06-22 | 2022-04-26 | Novartis Ag | Antibody molecules to CD73 and uses thereof |
| EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
| CA3081602A1 (en) | 2017-11-16 | 2019-05-23 | Novartis Ag | Combination therapies |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| CN108484640B (zh) * | 2018-05-22 | 2020-09-15 | 南京华威医药科技集团有限公司 | 一种抗肿瘤的细胞凋亡蛋白抑制剂 |
| TWI869346B (zh) | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| TWI848953B (zh) | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| JP7515175B2 (ja) | 2018-07-31 | 2024-07-12 | ファイメクス株式会社 | 複素環化合物 |
| US20210361774A1 (en) | 2018-10-16 | 2021-11-25 | Dana-Farber Cancer Institute, Inc. | Degraders of wild-type and mutant forms of lrrk2 |
| WO2020148447A1 (en) | 2019-01-17 | 2020-07-23 | Debiopharm International S.A. | Combination product for the treatment of cancer |
| TWI894135B (zh) | 2019-01-25 | 2025-08-21 | 德商百靈佳殷格翰國際股份有限公司 | 編碼ccl21之重組棒狀病毒 |
| EP3947368B1 (en) | 2019-04-04 | 2025-09-03 | Dana-Farber Cancer Institute, Inc. | Bifunctional compounds comprising a cdk2/5 ligand, a linker and a e3 ubiquitin ligase binding degron for the treatment of cancer |
| US20230081720A1 (en) | 2019-05-20 | 2023-03-16 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| EP4006037A4 (en) | 2019-07-31 | 2023-12-13 | Fimecs, Inc. | HETEROCYCLIC COMPOUND |
| CN114502590A (zh) | 2019-09-18 | 2022-05-13 | 诺华股份有限公司 | Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法 |
| EP4034102A1 (en) | 2019-09-25 | 2022-08-03 | Debiopharm International SA | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma |
| JP2023510426A (ja) | 2020-01-20 | 2023-03-13 | アストラゼネカ・アクチエボラーグ | 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤 |
| EP4161544A1 (en) | 2020-06-03 | 2023-04-12 | Boehringer Ingelheim International GmbH | Recombinant rhabdovirus encoding for a cd80 extracellular domain fc-fusion protein |
| MX2023006010A (es) | 2020-11-24 | 2023-06-08 | Novartis Ag | Anticuerpos anti-cd48, conjugados de anticuerpo-farmaco, y usos de los mismos. |
| CA3202759A1 (en) | 2020-11-24 | 2022-06-02 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| US20240376094A2 (en) | 2021-02-02 | 2024-11-14 | Les Laboratoires Servier | Selective bcl-xl protac compounds and methods of use |
| CA3256012A1 (en) | 2022-05-20 | 2023-11-23 | Les Laboratoires Servier | ANTIBODY-DRUG CONJUGATES, MET INHIBITORS BCL-XL, AND THEIR METHODS OF USE |
| KR20250027281A (ko) | 2022-05-20 | 2025-02-25 | 노파르티스 아게 | Epha2 bcl-xl 억제제 항체-약물 접합체 및 그의 사용 방법 |
| KR20250160354A (ko) | 2023-03-10 | 2025-11-12 | 노파르티스 아게 | Panras 억제제 항체-약물 콘쥬게이트 및 이의 사용 방법 |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
| TW202540185A (zh) | 2023-11-22 | 2025-10-16 | 法商施維雅藥廠 | 抗cd74抗體藥物結合物及其使用方法 |
| WO2025215536A1 (en) | 2024-04-10 | 2025-10-16 | Novartis Ag | Macrocyclic panras inhibitors for the treatment of cancer |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2714880A1 (de) * | 1977-04-02 | 1978-10-26 | Hoechst Ag | Cephemderivate und verfahren zu ihrer herstellung |
| JPS59141547A (ja) * | 1983-02-01 | 1984-08-14 | Eisai Co Ltd | 鎮痛作用を有する新規ペプタイドおよび製法 |
| FR2575753B1 (fr) * | 1985-01-07 | 1987-02-20 | Adir | Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| DK167813B1 (da) * | 1989-12-07 | 1993-12-20 | Carlbiotech Ltd As | Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat |
| US5559209A (en) * | 1993-02-18 | 1996-09-24 | The General Hospital Corporation | Regulator regions of G proteins |
| US6472172B1 (en) * | 1998-07-31 | 2002-10-29 | Schering Aktiengesellschaft | DNA encoding a novel human inhibitor-of-apoptosis protein |
| KR20020025959A (ko) | 2000-05-23 | 2002-04-04 | 버텍스 파마슈티칼스 인코포레이티드 | 카스파제 억제제 및 이의 용도 |
| US6608026B1 (en) * | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
| US20020160975A1 (en) * | 2001-02-08 | 2002-10-31 | Thomas Jefferson University | Conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO for mediating apoptosis |
| WO2003040172A2 (en) * | 2001-11-09 | 2003-05-15 | Aegera Therapeutics, Inc. | Methods and reagents for peptide-bir interaction screens |
| WO2004005248A1 (en) | 2002-07-02 | 2004-01-15 | Novartis Ag | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
| EP1578777B1 (en) * | 2002-07-15 | 2008-11-26 | The Trustees of Princeton University | Iap binding compounds |
| US20040171554A1 (en) * | 2003-02-07 | 2004-09-02 | Genentech, Inc. | Compositions and methods for enhancing apoptosis |
| CA2543897A1 (en) * | 2003-11-13 | 2005-06-02 | Genentech, Inc. | Compositions and methods for screening pro-apoptotic compounds |
| CA2553871A1 (en) * | 2004-01-16 | 2005-08-04 | The Regents Of The University Of Michigan | Smac peptidomimetics and the uses thereof |
| SE527038C2 (sv) * | 2004-02-26 | 2005-12-13 | Ingenjoers N Per Oskar Persson | Kassett och apparat för vätskefrysning |
| JP4674231B2 (ja) * | 2004-03-01 | 2011-04-20 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | ２量体小分子アポトーシス増強剤 |
| PL2253614T3 (pl) * | 2004-04-07 | 2013-03-29 | Novartis Ag | Inhibitory IAP |
| SI1778718T1 (sl) | 2004-07-02 | 2015-01-30 | Genentech, Inc. | Inhibitorji IAP |
| KR20120127754A (ko) | 2004-12-20 | 2012-11-23 | 제넨테크, 인크. | Ｉａｐ의 피롤리딘 억제제 |
| US20060218632A1 (en) * | 2005-03-28 | 2006-09-28 | Cisco Technology, Inc.; | Method and system for installing premise equipment |
| CA2666112A1 (en) * | 2006-10-12 | 2008-04-17 | Novartis Ag | Pyrrolydine derivatives as iap inhibitors |
| WO2008073306A1 (en) * | 2006-12-07 | 2008-06-19 | Novartis Ag | Organic compounds |
-
2007
- 2007-07-26 PE PE2011000111A patent/PE20110217A1/es not_active Application Discontinuation
- 2007-07-26 PE PE2011000114A patent/PE20110224A1/es active IP Right Grant
- 2007-07-26 PE PE2007000978A patent/PE20080951A1/es active IP Right Grant
- 2007-07-26 PE PE2011000112A patent/PE20110218A1/es not_active Application Discontinuation
- 2007-07-26 PE PE2011000113A patent/PE20110220A1/es not_active Application Discontinuation
- 2007-07-31 HR HRP20130373TT patent/HRP20130373T1/hr unknown
- 2007-07-31 EP EP07813569A patent/EP2051990B1/en active Active
- 2007-07-31 EP EP12184700A patent/EP2537850A1/en not_active Withdrawn
- 2007-07-31 ES ES12184747.9T patent/ES2559042T3/es active Active
- 2007-07-31 EA EA200900227A patent/EA021671B1/ru not_active IP Right Cessation
- 2007-07-31 SI SI200731218T patent/SI2051990T1/sl unknown
- 2007-07-31 US US12/376,057 patent/US8552003B2/en active Active
- 2007-07-31 AR ARP070103375A patent/AR062159A1/es not_active Application Discontinuation
- 2007-07-31 KR KR1020097004264A patent/KR101087878B1/ko active Active
- 2007-07-31 MY MYPI20090334 patent/MY150460A/en unknown
- 2007-07-31 EA EA201401247A patent/EA201401247A1/ru unknown
- 2007-07-31 GE GEAP200711084A patent/GEP20115251B/en unknown
- 2007-07-31 AU AU2007281230A patent/AU2007281230B2/en active Active
- 2007-07-31 CA CA2658525A patent/CA2658525C/en active Active
- 2007-07-31 DK DK07813569.6T patent/DK2051990T3/da active
- 2007-07-31 JP JP2009523001A patent/JP4875749B2/ja active Active
- 2007-07-31 NZ NZ574393A patent/NZ574393A/en not_active IP Right Cessation
- 2007-07-31 ES ES07813569T patent/ES2405947T3/es active Active
- 2007-07-31 MX MX2009001212A patent/MX2009001212A/es active IP Right Grant
- 2007-07-31 CN CN2007800329568A patent/CN101511860B/zh active Active
- 2007-07-31 PT PT78135696T patent/PT2051990E/pt unknown
- 2007-07-31 KR KR1020117002855A patent/KR101245945B1/ko active Active
- 2007-07-31 PL PL07813569T patent/PL2051990T3/pl unknown
- 2007-07-31 CN CN201110446951.8A patent/CN102558165B/zh active Active
- 2007-07-31 WO PCT/US2007/074790 patent/WO2008016893A1/en not_active Ceased
- 2007-07-31 UA UAA200900768A patent/UA95485C2/uk unknown
- 2007-07-31 BR BRPI0714803A patent/BRPI0714803B8/pt active IP Right Grant
- 2007-07-31 ME MEP-2009-19A patent/ME00585B/me unknown
- 2007-07-31 EP EP12184747.9A patent/EP2537846B1/en active Active
- 2007-08-01 CL CL200702234A patent/CL2007002234A1/es unknown
- 2007-08-01 TW TW096128289A patent/TWI408133B/zh not_active IP Right Cessation
- 2007-08-02 PA PA20078740901A patent/PA8740901A1/es unknown
- 2007-08-02 JO JO2007318A patent/JO2848B1/en active
-
2009
- 2009-01-16 ZA ZA2009/00371A patent/ZA200900371B/en unknown
- 2009-01-16 CR CR10567A patent/CR10567A/es unknown
- 2009-01-19 IL IL196596A patent/IL196596A/en active IP Right Grant
- 2009-01-22 NI NI2009000081A patent/NI200900081A/es unknown
- 2009-01-22 NI NI200900008A patent/NI200900008A/es unknown
- 2009-01-29 CU CU20090017A patent/CU23866B1/es active IP Right Grant
- 2009-01-30 GT GT200900019A patent/GT200900019A/es unknown
- 2009-01-30 TN TN2009000034A patent/TN2009000034A1/fr unknown
- 2009-01-30 HN HN2009000214A patent/HN2009000214A/es unknown
- 2009-02-02 SV SV2009003160A patent/SV2009003160A/es active IP Right Grant
- 2009-02-17 MA MA31648A patent/MA30652B1/fr unknown
- 2009-02-25 NO NO20090878A patent/NO342230B1/no not_active IP Right Cessation
- 2009-02-26 SM SM200900013T patent/SMP200900013B/it unknown
-
2011
- 2011-02-02 CU CU2011000027A patent/CU24004B1/es active IP Right Grant
-
2012
- 2012-09-07 US US13/606,676 patent/US8546336B2/en active Active
-
2013
- 2013-04-16 DO DO2013000084A patent/DOP2013000084A/es unknown
- 2013-08-29 US US14/013,666 patent/US20140004101A1/en not_active Abandoned
- 2013-10-23 GT GT200900019AK patent/GT200900019AA/es unknown
-
2014
- 2014-02-20 IL IL231079A patent/IL231079A/en active IP Right Grant
- 2014-12-03 CR CR20140555A patent/CR20140555A/es unknown
-
2015
- 2015-01-22 IL IL236883A patent/IL236883A0/en unknown
-
2017
- 2017-12-04 AR ARP170103398A patent/AR110313A2/es unknown
-
2018
- 2018-09-17 AR ARP180102641A patent/AR112816A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT200900019AA (es) | Peptidomimeticos de smac utiles como inhibidores de proteinas de apoptosis (aip) | |
| BRPI0815708A8 (pt) | composto derivado de benzilbenzeno como inibidor de sglt, composição farmacêutica, e, uso de um composto | |
| GT201100181A (es) | "inhibidores de proteina cinasa" | |
| CL2012001911A1 (es) | Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa. | |
| ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
| CL2007002166A1 (es) | Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer. | |
| CL2008002430A1 (es) | Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc. | |
| CO6771447A2 (es) | Ciclopropilaminas como inhibidores de desmetilasa 1 específica de lisina | |
| ECSP099445A (es) | Quinazolinas para la inhibición de pdk1 | |
| CL2008003690A1 (es) | Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos. | |
| UY32622A (es) | Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta) | |
| CR11684A (es) | Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa | |
| SV2009003389A (es) | Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer | |
| GT200900192A (es) | Derivados de imidazol como inhibidores de proteina de uso de cinesina (eg-5).- | |
| MX2012013206A (es) | Inhibidores de quinasa biciclica fusionada. | |
| DOP2009000200A (es) | Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pimiridina como inhibidores hsp-90 para tratar el cancer | |
| CL2011000258A1 (es) | Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion. | |
| CO6280510A2 (es) | Pirimidil ciclopentanos hidroxilados como inhibidores de akt proteina quinasa | |
| CL2011000168A1 (es) | Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer. | |
| SV2010003773A (es) | 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos | |
| CL2011001850A1 (es) | Uso de un compuesto nitrogenado heterociclico sustituido para el tratamiento de cánceres tales como cáncer de colon o mieloma múltiple;composición farmacéutica que comprende al compuesto. | |
| AR075783A1 (es) | Peptido para el tratamiento profilactico o terapeutico de tumores de la piel en estadios iniciales | |
| UY30514A1 (es) | Compuestos organicos | |
| CU20110025A7 (es) | Peptidomiméticos de smac útiles como inhibidores de proteínas de apoptosis (iap) | |
| CU20110026A7 (es) | Peptidomiméticos de smac útiles como inhibidores de proteínas de apoptosis (iap) |